ReproCell

ReproCell SGA/Revenue

The SGA to Revenue Ratio of ReproCell (4978.T) as of Oct 10, 2026 is 55.89 %. In the previous year, SGA to Revenue Ratio was 41.72 % — a change of 33.96% (higher).

SGA/Revenue

55.89 %

YoY

33.96%

Last updated:

SGA to Revenue Ratio of ReproCell is 2026 55.89 % . SGA to Revenue Ratio of ReproCell was 2025 41.72 % . It decreases by 33.96% higher compared to the previous year.

The ReproCell SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2019
92.27 JPY
Jan 1, 2020
77.41 JPY
Jan 1, 2021
67.54 JPY
Jan 1, 2022
40.96 JPY
Jan 1, 2023
33.72 JPY
Jan 1, 2024
47.19 JPY
Jan 1, 2025
41.72 JPY
Jan 1, 2026
55.89 JPY
The ReproCell SGA/Revenue history
YEARSGA/RevenueYoY
55.89 %+33.96%
41.72 %-11.60%
47.19 %+39.94%
33.72 %-17.67%
40.96 %-39.35%
67.54 %-12.76%
77.41 %-16.10%
92.27 %-29.68%
131.21 %+32.68%
98.90 %-16.83%
118.91 %-8.46%
129.90 %+161.13%
49.75 %—
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

SGA to Revenue Ratio of ReproCell is 55.89 % in 2026.

SGA to Revenue Ratio of ReproCell changed from 41.72 % to 55.89 %, representing a 33.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

Margins — ReproCell

All Key Metrics — ReproCell